(RTTNews) – Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its supplemental New Drug Application or sNDA seeking approval of a higher dose of nusinersen for the treatment of spinal muscular atr
Uncategorized
FDA Requests Addl. Technical Info For Biogen's High-Dose Nusinersen Application For SMA Treatment
(RTTNews) – Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its supplemental New Drug Application or sNDA seeking approval of a higher dose of nusinersen for the treatment of spinal muscular atr
Major stock exchanges worldwide responded positively to trade agreement developments
Related News
frank orange
frank orange is a senior financial markets correspondent with over 15 years of experience covering global economic developments.